Two-drug combination for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a combination of two drugs — a chemotherapy called liposomal irinotecan and an immunotherapy drug called enlonstobart — for women whose ovarian cancer has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- Your ovarian, fallopian tube, or peritoneal cancer has come back within 6 months after your last platinum-based chemo.
- You have a tumor tissue sample available for a PD-L1 test.
- You have at least one tumor that can be measured on a scan.
- You are physically active and able to care for yourself (ECOG 0 or 1).
- You have not had immunotherapy before and are not currently pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs (trastuzumab rezetecan and bevacizumab) for women with ovarian cancer that has returned after initial treatment. The goal is to see if this combination helps control the cancer longer.
This trial tests whether adding immunotherapy (a treatment that boosts your immune system) to surgery helps people whose ovarian cancer has returned and is sensitive to chemotherapy. It aims to see if this combination can improve outcomes for patients with certain biomarkers.
This trial tests a combination of three drugs—benmelstobart (an immunotherapy), anlotinib (a targeted therapy that blocks blood vessel growth to tumors), and low-dose cyclophosphamide (a chemotherapy drug)—to see if they can shrink tumors or slow down cancer in people with recurrent ovarian, fallopian tube, or peritoneal cancer. The goal is to find a new treatment option for those whose cancer has returned despite previous therapies.
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
This trial tests a new combination of drugs for ovarian cancer that has come back after responding to platinum chemotherapy. The goal is to see if adding these drugs helps control the cancer longer.
Hear when a new Platinum-resistant Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.